CDI-988 + Placebo

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Norovirus

Conditions

Norovirus

Trial Timeline

Mar 1, 2026 → Dec 1, 2026

NCT ID

NCT07198139

About CDI-988 + Placebo

CDI-988 + Placebo is a phase 1/2 stage product being developed by Cocrystal Pharma for Norovirus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07198139. Target conditions include Norovirus.

What happened to similar drugs?

0 of 1 similar drugs in Norovirus were approved

Approved (0) Terminated (0) Active (1)

🔄mRNA-1403ModernaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07198139	Phase 1/2	Recruiting	Mar 1, 2026	Dec 1, 2026	Norovirus
NCT05977140	Phase 1	Completed	Sep 27, 2023	Jul 23, 2025	Healthy Volunteers

Competing Products

13 competing products in Norovirus

See all competitors

Product	Company	Stage	Hype Score
mRNA-1403	Moderna	Phase 2	0
mRNA-1403	Moderna	Phase 3	0
VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets	Vaxart	Phase 1	19
VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet	Vaxart	Phase 1	19
VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T	Vaxart	Phase 1	23
VXA-G1.1-NN	Vaxart	Phase 1/2	22
VXA-G1.1-NN Oral Vaccine	Vaxart	Phase 1	19
VXA-G1.1-NN	Vaxart	Phase 1	19
Norwalk GI.1 Virus	Vaxart	Phase 1	19
VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum	Vaxart	Phase 1/2	22
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + Placebo	Vaxart	Phase 2	25
VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets	Vaxart	Phase 1	19
VXA-GI.1.NN + Placebo Tablet	Vaxart	Phase 1	19